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A bs tr ac t
Background
Establishing the genetic basis of phenotypes such as skeletal dysplasia in model 
organisms can provide insights into biologic processes and their role in human 
disease.
Methods
We screened mutagenized mice and observed a neonatal lethal skeletal dysplasia with 
an autosomal recessive pattern of inheritance. Through genetic mapping and posi-
tional cloning, we identified the causative mutation.
Results
Affected mice had a nonsense mutation in the thyroid hormone receptor interactor 
11 gene (Trip11), which encodes the Golgi microtubule-associated protein 210 
(GMAP-210); the affected mice lacked this protein. Golgi architecture was disturbed 
in multiple tissues, including cartilage. Skeletal development was severely impaired, 
with chondrocytes showing swelling and stress in the endoplasmic reticulum, ab-
normal cellular differentiation, and increased cell death. Golgi-mediated glycosyla-
tion events were altered in fibroblasts and chondrocytes lacking GMAP-210, and 
these chondrocytes had intracellular accumulation of perlecan, an extracellular 
matrix protein, but not of type II collagen or aggrecan, two other extracellular ma-
trix proteins. The similarities between the skeletal and cellular phenotypes in these 
mice and those in patients with achondrogenesis type 1A, a neonatal lethal form of 
skeletal dysplasia in humans, suggested that achondrogenesis type 1A may be caused 
by GMAP-210 deficiency. Sequence analysis revealed loss-of-function mutations in 
the 10 unrelated patients with achondrogenesis type 1A whom we studied.
Conclusions
GMAP-210 is required for the efficient glycosylation and cellular transport of mul-
tiple proteins. The identification of a mutation affecting GMAP-210 in mice, and 
then in humans, as the cause of a lethal skeletal dysplasia underscores the value of 
screening for abnormal phenotypes in model organisms and identifying the caus-
ative mutations.
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The presence of the Golgi apparatus in all cell types suggests that it is indispens-able. Although cultured cells are able to sur-
vive when their well-structured Golgi architecture 
is transiently disrupted chemically or through RNA 
interference (RNAi),1 the requirement for an intact 
Golgi apparatus during development has not been 
studied. In this article, we describe mice in which 
the Golgi architecture is disrupted in multiple tis-
sues by a loss-of-function mutation in the thyroid 
hormone receptor interactor 11 gene (Trip11), which 
encodes the Golgi microtubule-associated protein 
210 (GMAP-210 — also known as TRIP230 and 
TRIP11). Golgins constitute a family of Golgi-
associated proteins that serve either as tethering 
factors that facilitate vesicle fusion to Golgi com-
partments or as structural proteins that maintain 
Golgi architecture.1,2 We observed that mice lack-
ing GMAP-210 die from a skeletal dysplasia that 
shares phenotypic features with achondrogenesis 
type 1A, a lethal, autosomal recessive, skeletal dys-
plasia in humans.3 We tested for mutations af-
fecting GMAP-210 in patients with achondrogen-
esis type 1A.
Me thods
Identification and Characterization  
of GMAP-210–deficient Mice
We carried out a screen for recessive mutations af-
fecting late embryonic development in mice treat-
ed with the N-ethyl-N-nitrosourea (ENU) mutagen, 
as previously described.4 We used whole-genome, 
single-nucleotide-polymorphism (SNP) analysis5 
to map the locus harboring the etiologic mutation 
and used a polymerase-chain-reaction assay to am-
plify and sequence candidate genes in accordance 
with standard methods.
DNA Sequence Analysis of TRIP11
We sequenced TRIP11 in patients with achondro-
genesis type 1A. We confirmed mutations with 
the use of DNA obtained from patients’ parents; 
in the event that parental DNA was unavailable, 
we used subcloning followed by sequence analy-
sis to show that the mutant alleles making up a 
compound heterozygous mutation were derived 
from different parental chromosomes.
DNA samples from patients with a diagnosis 
of achondrogenesis type 1A (Online Mendelian 
Inheritance in Man number, 200600) were pro-
vided by three referral centers that specialize in 
the clinical, radiologic, and histologic character-
ization of skeletal dysplasia. Each referral center 
obtained written informed consent to collect and 
analyze DNA. The institutional review board at 
Children’s Hospital Boston approved the analysis 
of DNA samples that would be stripped of identi-
fying information before being transferred from 
the referral centers.
Transport Assay
We prepared adenovirus expressing a temperature-
sensitive vesicular stomatitis viral G protein fused 
to green f luorescence protein (VSVGts–GFP), as 
previously described.6 We studied VSVGts–GFP pro-
cessing in heterozygous and mutant skin fibro-
blasts grown in six-well culture plates. The assay 
was repeated three times on separate days and per-
formed in triplicate each time. (See the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org, for details on fibroblast cul-
tures; skeletal preparations; histologic analysis; 
RNA in situ hybridization; electron microscopy; 
monitoring of chondrocyte differentiation, pro-
liferation, and apoptosis; immunofluorescence 
staining of cultured cells and frozen sections; 
immunodetection of GMAP-210; and an assay for 
hedgehog signaling.)
R esult s
Trip11 and the Mutant Mouse Phenotype
After initiating mutagenesis with ENU,4 we iden-
tified mice with a neonatal lethal phenotype that 
was autosomal recessive. Affected mice had short 
limbs, small thoracic cages, short snouts, domed 
skulls, and in some cases, omphalocele (Fig. 1A). 
Skeletal preparations revealed delayed mineraliza-
tion of intramembranous and endochondral bone 
(Fig. 1B). As compared with wild-type mice, new-
born mutant mice lacked vertebral-body ossifica-
tion (Fig. 1B). Alveolar formation in the lungs 
was also decreased in newborn mutant mice as 
compared with newborn wild-type mice (Fig. 1 
in the Supplementary Appendix).
For the screen, we outcrossed mutagenized 
C57BL/6J mice with wild-type FVB/N mice4 and 
used a panel of 394 single-nucleotide polymor-
phisms (SNPs) spanning the mouse genome to 
facilitate genetic mapping.5 After analysis of 10 
mutant mice, we located the causative mutation 
within a 17-Mb region on chromosome 12, and 
analysis of additional mice narrowed the candi-
date interval to 3.7 Mb. We sequenced four genes 
in this interval before identifying a nonsense mu-
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Figure 1. Effects of Trip11 Mutation in Mice.
Panel A shows a wild-type fetal mouse and a fetal mouse with an induced nonsense mutation in Trip11, the gene encoding GMAP-210, 
on embryonic day 18.5. The mouse with the mutation has a domed skull, short snout, short trunk, short limbs, and omphalocele (ar-
rowhead). In Panel B (top), the staining of cartilage with Alcian blue and bone with alizarin red on embryonic day 17.5 in a wild-type 
mouse and a mouse with the Trip11 mutation reveals the absence of mineralization in the skull (arrowhead), rib cage, and limbs (ar-
rows) in the mutant. In Panel B, bottom, staining of cartilage and bone in the vertebral columns of newborn wild-type and mutant mice 
reveals the absence of mineralization in the vertebral body of the mutant (arrow). In Panel C, immunoblotting of GMAP-210 in immuno-
precipitated samples of primary skin fibroblasts from  wild-type mouse, a heterozygous mouse, and a mutant mouse shows that 
GMAP-210 is not detectable in the mutant fibroblasts. IgG, which was used in the immunoprecipitation reaction, also serves as a load-
ing control. In Panel D, in situ hybridization of specimens of wild-type shoulder girdle and humerus obtained on embryonic day 15.5, 
with the use of Trip11 antisense and sense RNA probes, shows the expression of Trip11 in all cell types, with an absence of increased ex-
pression in cartilage (arrow) and bone (arrowhead). Red indicates Trip11 mRNA expression. The nuclei of cells have been stained with 
4′,6-diamidino-2-phenylindole, which fluoresces blue. Panel E shows histologic sections of the shoulder girdle and humerus from wild-
type and mutant mice, obtained on embryonic day 15.5 and stained with nuclear-fast red and Alcian blue. The cartilage in the mutant 
humerus shows less staining with Alcian blue and contains chondrocytes with increased cell sizes. The mutant specimen also lacks an 
organized growth zone of flattened chondrocytes and a primary ossification (PO) center, although it does have a bone collar (arrow). 
Higher magnification images from the wild-type and mutant growth zones show the increased size of chondrocytes and the lack of chon-
drocyte columnar organization in the mutant cartilage.
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tation (c.5003T→A, p.L1668X) in Trip11 in the mu-
tant mice. Immunoblotting with an antibody that 
recognizes an epitope encoded by a region of the 
complementary DNA that precedes the truncating 
mutation showed that GMAP-210 was absent in 
protein extracts from mutant cells (Fig. 1C).
To confirm that the phenotype resulted from a 
mutation in Trip11, mice carrying the nonsense 
mutation were crossed with mice that were heter o-
zygous for another inactivating Trip11 allele.7 Off-
spring that were compound heterozygotes (i.e., 
carrying the ENU-induced Trip11L1668X nonsense 
mutation on one allele and a different Trip11 in-
activating mutation on the other allele) had the 
same phenotype as offspring that were homozy-
gous for the nonsense mutation (data not shown), 
proving that the phenotype was the result of a 
GMAP-210 deficiency. We also performed RNA 
in situ hybridization to determine which tissues 
normally express Trip11 messenger RNA (mRNA) 
and observed widespread expression (Fig. 1D). 
Therefore, enhanced or restricted expression of 
GMAP-210 in the developing skeleton does not 
explain the prominent skeletal phenotype in the 
mutant animals.
Cellular Effects of GMAP-210 Deficiency
On embryonic day 13.5, wild-type chondrocytes at 
the centers of humeri start to undergo hypertro-
phic differentiation, which is associated with an 
increase in cell size. The humeri of the mutant mice 
had hypertrophic chondrocytes that were smaller 
than those in wild-type mice and had proliferating 
chondrocytes that were larger than those in wild-
type mice (data not shown). These differences be-
came more pronounced by embryonic day 15.5, 
when mutant chondrocytes in the epiphysis and 
metaphysis were markedly larger than normal 
(Fig. 1E). Furthermore, mutant chondrocytes failed 
to form an organized columnar growth zone and 
produced less extracellular matrix, as indicated 
by staining with Alcian blue (Fig. 1E).
RNA in situ hybridization with mRNA probes 
that are specific for proliferating chrondrocytes 
(Col2a1), chondrocytes that are about to undergo 
hypertrophic differentiation (Ppr), and those that 
are in the early stage of hypertrophic differen-
tiation (Col10a1) revealed a delay in differentia-
tion (Fig. 2, and Fig. 2 in the Supplementary Ap-
pendix). Expression of Col2a1 by embryonic day 
13.5 was identical in wild-type and mutant mice, 
whereas expression of the prehypertrophic marker, 
Ppr, and the hypertrophic marker, Col10a1, was re-
duced in the mutant mice (Fig. 2A in the Supple-
mentary Appendix). By embryonic day 14.5, the 
expression levels of Col10a1 in the humeri of mu-
tant mice was similar to that in wild-type mice, 
but in the mutant mice, the expression domain 
had not divided into two growth zones, a find-
ing that is consistent with delayed hypertrophic 
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Figure 2. Effects of GMAP-210 Deficiency on Hypertrophic Differentiation, 
Proliferation, and Apoptosis of Chondrocytes in Mice.
Panel A shows sections through the primary ossification centers of humeri 
from wild-type and mutant mice that were obtained on embryonic day 14.5, 
stained with Alcian blue, and subjected to in situ hybridization. Col10a1 ex-
pression has not separated into two domains in the mutant humerus, and 
there is no cartilage expression of the late-stage hypertrophic chondrocyte 
markers vascular endothelial g owth f ctor (Vegf ) and matrix metallopro-
teinase 13 (Mmp13). Mmp13 is expressed only by periosteal osteoclasts in 
the mutant humerus (arrowheads). Sections through shoulder joints and 
humeri obtained on embryonic day 15.5 show that there is no difference in 
the incorporation of bromodeoxyuridine (BrdU) between wild-type and mu-
tant chondrocytes adjacent to the joint (Panel B, arrowheads) but that in 
the mutant cartilage there is no other area of BrdU incorporation. Use of 
the terminal deoxynucleotidyl transferase dUTP biotin nick end labeling 
(TUNEL) assay on histologic sections of elbow joints obtained on embry-
onic day 17.5 show that the mutant humerus (H) and ulna (U) have many 
TUNEL-positive cells, which appear blue in the sections, whereas the wild-
type humerus and ulna do not (Panel C).
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differentiation (Fig. 2A). Furthermore, on embry-
onic day 14.5, expression of vascular endothelial 
growth factor (Vegf), a marker of late hypertrophic 
differentiation, and matrix metalloproteinase 13 
(Mmp13), a marker of terminal differentiation, was 
absent from the mutant humeri, indicating im-
paired terminal differentiation (Fig. 2A). Finally, 
on embryonic day 18.5, expression of hypertro-
phic-differentiation markers became undetectable 
in the mutant mice (Fig. 2B in the Supplementary 
Appendix). Thus, chondrocyte hypertrophic dif-
ferentiation was delayed in the mutant mice, with 
worsening at later developmental stages and a 
complete absence of differentiation by embryonic 
day 18.5.
Since the mutant humeri failed to increase in 
size, we performed bromodeoxyuridine incorpo-
ration assays to assess chondrocyte proliferation. 
By embryonic day 15.5, there were no proliferat-
ing cells in the center of the epiphysis or in the 
presumptive columnar zone in the humeri of the 
mutant mice, in contrast to the findings in the 
wild-type mice (Fig. 2B). The decreased expression 
of chondrocyte marker genes in the mutant mice 
on embryonic day 18.5 (Fig. 2B in the Supplemen-
tary Appendix) suggested that the chondrocytes 
were dying. This was confirmed with the use of 
the terminal deoxynucleotidyl transferase dUTP 
biotin nick end labeling (TUNEL) assay on embry-
onic day 17.5, which showed apoptotic chondro-
cytes throughout mutant humeri but not in wild-
type humeri (Fig. 2C).
Endoplasmic Reticulum and Golgi 
Organization and Processing in Mutant Cells
Transmission electron microscopy of mutant chon-
drocytes and osteoblasts revealed swelling of the 
endoplasmic reticulum (Fig. 3A and 3B). Although 
GMAP-210 was expressed in other cell types (e.g., 
fibroblasts, endothelial cells, pericytes, myocytes, 
hepatocytes, and keratinocytes), these cells had en-
doplasmic reticulum of normal appearance (Fig. 
3A in the Supplementary Appendix). Because mu-
tant chondrocytes contained swollen endoplasmic 
reticulum, we assayed the expression of the en-
doplasmic reticulum stress-response gene, heat-
shock protein 5 (Hspa5-Bip),8 and found that there 
was greater Hspa5-Bip expression in mutant chon-
drocytes than in wild-type chondrocytes (Fig. 3A 
in the Supplementary Appendix). Chondrocytes 
from mutant mice also lacked a typical Golgi ap-
paratus (Fig. 3C). Instead of displaying a Golgi ap-
paratus with stacked cisternal organization, mu-
tant chondrocytes contained an aggregation of 
vesicle-like structures. Electron microscopical ex-
amination of other tissues on embryonic day 15.5 
revealed an abnormal Golgi apparatus in the kid-
ney but not in the intestine or lung (Fig. 3C, and 
Fig. 3C in the Supplementary Appendix). Primary 
dermal fibroblast cultures from the mutant mice 
showed an abnormally condensed Golgi apparatus 
as compared with that in wild-type fibroblasts (Fig. 
4A). However, the cis- and trans-Golgi compartments 
in the mutant fibroblasts were preserved, as indi-
cated by the adjacent, nonoverlapping localization 
of Golgi matrix protein 130 (GM130) (a cis-Golgi 
protein) and ADP-ribosylation factor–like 1 (Arl1) 
(a trans-Golgi protein) (Fig. 4A).
Primary chondrocyte cultures from mice lack-
ing GMAP-210 grew poorly and failed to differen-
tiate. Therefore, we used primary skin fibroblasts 
from mice that were heterozygous or homozygous 
for the nonsense mutation to evaluate endoplas-
mic reticulum and Golgi function. We infected 
these fibroblasts with adenovirus expressing a 
thermoreversible folding mutant of VSVGts–GFP; 
this particular mutant is unfolded and retained 
within the endoplasmic reticulum at 40°C, but it 
can fold properly and transit through the Golgi 
apparatus at 32°C (Fig. 4, and Fig. 4A in the Supple-
mentary Appendix). VSVGts–GFP processing dif-
fered between homozygous and hetero zygous cells 
(Fig. 4C), probably because of altered glycosyla-
tion of VSVGts–GFP within the Golgi of homozy-
gous mutant cells rather than impaired transit 
through the Golgi. We could make this distinc-
tion because the transport of VSVGts–GFP to the 
cell surface was similar in homozygous and heterozy-
gous cells (Fig. 4 in the Supplementary Appendix).
To confirm that post-translational modifica-
tions were altered in cells deficient in GMAP-210, 
we stained cultured fibroblasts and skeletal sec-
tions from wild-type and mutant mice with lectin 
GS-II. This form of lectin, isolated from the seeds 
of the tropical African legume Griffonia simplicifolia, 
preferentially binds to the terminal glycan struc-
ture N-acetylglucosamine.9 Increased lectin GS-II 
binding indicates impaired glycosylation because 
N-acetylglucosamine is uncommon in correctly 
glycosylated proteins. As compared with wild-type 
fibroblasts, mutant primary dermal fibroblasts 
showed increased lectin GS-II binding along cell 
surfaces (Fig. 5 in the Supplementary Appendix), 
which is consistent with incomplete modification 
of cell-surface proteins. Furthermore, we observed 
a marked increase in lectin GS-II binding in the 
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cartilage of mutant mice (as compared with that 
of wild-type mice), with most of the binding oc-
curring intracellularly (Fig. 5 in the Supplementary 
Appendix). Lectin GS-II has previously been shown 
to bind glycans that are being synthesized in the 
medial- and trans-Golgi compartments.10 There-
fore, our result is consistent with impaired Golgi 
function in chondrocytes that lack GMAP-210.
Transmission electron microscopy of the ex-
tracellular matrix of cartilage from the humeri 
revealed that the collagen fibrils were similar in 
content in wild-type and mutant mice (Fig. 4D). 
Immunofluorescence light microscopy performed 
with the use of anti–type II collagen antibodies 
showed that the amount and distribution of this 
collagen in the cartilage did not differ between 
wild-type and mutant mice (Fig. 6 in the Supple-
mentary Appendix), a finding that is consistent 
with electron-microscopical findings. Similarly, 
there were no differences between wild-type and 
mutant mice with respect to antibodies directed 
against the polypeptide cores of cartilage oligo-
meric matrix protein and aggrecan (Fig. 6 in the 
Supplementary Appendix). In contrast, proteogly-
can aggregates in cartilage, seen on electron mi-
croscopy as granulelike structures, were clearly 
smaller in the mutant mice than in the wild-type 
mice (Fig. 4D). Immunofluorescence studies with 
the use of an antibody directed against the poly-
peptide core of perlecan showed that mutant chon-
drocytes had an abnormal accumulation of this 
protein intracellularly (Fig. 4E), where it partially 
colocalized with the endoplasmic reticulum marker 
calreticulin. Perlecan, which is a prominent com-
ponent of basement membranes, is also secreted 
by dermal fibroblasts, and fibroblasts from mu-
tant mice retained perlecan intracellularly (Fig. 4F). 
Therefore, in addition to a general impairment in 
glycosylation, chondrocytes deficient in GMAP-210 
also differ from wild-type chondrocytes in the 
synthesis and secretion of specific proteins.
Figure 3. Swollen Endoplasmic Reticulum Cisternae 
and Abnormal Golgi Architecture in Murine Chondro-
cytes Lacking GMAP-210.
Electron micrographs of chondrocytes from wild-type 
and mutant humeri obtained on embryonic day 15.5 
show increased swelling of the endoplasmic reticulum 
in epiphyseal and columnar chondrocytes in mice lack-
ing GMAP-210 (Panel A), as compared with their wild-
type counterparts. A higher-magnification view of the 
epiphyseal chondrocytes showing ribosomes along the 
membrane surface of swollen cisternae in the mutant 
indicates that this is part of the endoplasmic reticu-
lum. Electron micrographs of osteoblasts from the 
bone collar of wild-type and mutant humeri (Panel B, 
top row, and at higher magnification in the bottom 
row) show increased swelling of the endoplasmic retic-
ulum in the mutant osteoblast. Panel C shows Golgi 
stacks in wild-type cartilage cells obtained on embry-
onic day 13.5 (top row, arrows) and wild-type kidney 
cells obtained on embryonic day 15.5 (bottom row, ar-
row) but not in mutant cells. The Golgi apparatus in 
the mutant cells consists of a collection of vesicles and 
enlarged cisternae (arrowheads).
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Figure 4. Impaired Post-Translational Protein Processing and Secretion in Murine Cells Lacking GMAP-210.
Panel A shows immunofluorescence staining for GM130, a cis-Golgi protein, and Arl1, a trans-Golgi protein, in wild-type and mutant pri-
mary skin fibroblasts. The immunofluorescence staining shows that mutant fibroblasts lack the reticular pattern that is present in wild-
type fibroblasts and instead have small vesicles that contain these Golgi-associated proteins. The gray scale is used to indicate fluores-
cence in the images for which only one protein is shown, and color is used for the merged images in which both proteins are shown. The 
merged images show that the structures containing GM130 (red) and Arl1 (green) do not overlap in wild-type or in mutant fibroblasts. 
Although the appearance of the Golgi apparatus differs between mutant fibroblasts and wild-type fibroblasts, the lack of overlap be-
tween GM130-containing vesicles and Arl1-containing vesicles indicates that mutant fibroblasts maintain the cis-trans polarity of the 
Golgi apparatus. Panels B and C show the results of a transport assay performed with vesicular stomatitis viral G protein fused to green 
fluorescence protein (VSVGts–GFP) in wild-type and mutant primary skin fibroblasts. In Panel B, fluorescence localization of VSVGts–
GFP and immunofluorescence localization of GM130 was performed in wild-type and mutant primary skin fibroblasts after the tempera-
ture of the infected cells had been shifted from 40°C to 32°C for 20 minutes. The gray scale is used to indicate fluorescence in the imag-
es for which only one protein is shown, and color is used for the merged images in which both proteins are shown. The merged images 
show that VSVGts–GFP (green) and GM130 (red) have substantial overlap (yellow) in wild-type and in mutant cells, indicating that trans-
port from the endoplasmic reticulum to the Golgi apparatus is not blocked in mutant cells. Panel C shows a Western blot analysis of a 
representative VSVGts–GFP transport assay and a graph depicting the means (±SD) of three independent experiments using primary 
skin fibroblasts from mice that were heterozygous or homozygous for the Trip11 mutation. After 1 hour and 3 hours at 32°C, cells that 
were completely lacking GMAP-210 (homozygous) had a lower mean ratio of endoglycosidase H–insensitive (endoH-i) VSVGts–GFP to 
endoglycosidase H–sensitive (EndoH-s) VSVGts–GFP than heterozygous cells; this finding is consistent with the view that the efficiency 
of Golgi glycosylation is reduced in fibroblasts with mutant GMAP-210. In Panel D, electron micrographs of extracellular matrix from epi-
physeal cartilage in wild-type and mutant humeri, obtained on embryonic day 17.5, show that the density of collagen fibrils is similar but 
that the glycosaminoglycan-containing complexes, which normally collapse and appear granular after the electron-microscopical fixation 
process (arrows), are smaller in the mutant extracellular matrix. Panel E shows changes in the distribution of perlecan (which can be 
seen with immunofluorescence detection and are depicted in the gray scale) between histologic sections of wild-type and mutant hu-
meri obtained on embryonic day 15.5 (top row). At higher magnification, immunofluorescence detection of perlecan (red) and the endo-
plasmic reticulum protein calreticulin (green) shows that mutant chondrocytes have greater retention of perlecan within their endoplas-
mic reticulum than do wild-type chondrocytes, as indicated by the stronger intracellular fluorescence and partial overlap (yellow) with 
calreticulin in the merged image. In Panel F, immunofluorescence detection of perlecan in the skin of wild-type and mutant mice on em-
bryonic day 15.5 shows an accumulation of perlecan in the mutant dermal fibroblasts (arrowheads). The arrows indicate the epidermal 
basement membrane; E denotes epidermis, and D dermis.
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Mutations in TRIP11 and Achondrogenesis 
Type 1A
Achondrogenesis type 1A, the neonatal lethal skel-
etal dysplasia with an autosomal recessive pattern 
of inheritance seen in our patients (Fig. 5A), has 
features that are similar to those of the mice with 
the Trip11 mutation. The absence of vertebral-body 
and skull ossification on radiography, the lack of 
organized columnar zones of proliferating chon-
drocytes on histologic analysis, the reduced ex-
pression of Col10a1 on immunohistochemical 
analy sis, and the expanded endoplasmic reticulum 
cisternae in chondrocytes on electron microscopy 
have all been reported in affected patients.3,11 We 
performed sequence analysis of TRIP11 in our 10 
unrelated patients with achondrogenesis type 1A 
and found loss-of-function mutations in each pa-
tient (Fig. 5B). Five mutations create termination 
codons, four alter the open-reading-frame, and 
two affect splice sites. Homozygous mutations 
were present in patients from consanguineous 
unions, and some mutations were found in more 
than one family.
Discussion
In 1898, Camillo Golgi described the diffuse retic-
ular network that bears his name.12 A half-century 
later, the ribbonlike cisternal architecture of this 
intracellular structure was observed with an elec-
tron microscope.13 How the Golgi apparatus forms, 
how it maintains its architecture, and what the 
relationship is between its structure and its func-
tions — which include glycosylation of proteins 
— remain incompletely understood.14 Golgin pro-
teins participate in these processes; ex vivo knock-
down of the golgins GMAP-210, golgin-84, and 
GM130 result in fragmentation of the Golgi ap-
paratus.15-17 Golgi fragmentation does not com-
pletely block the transport and processing of na-
scent proteins in cultured cells, but it does reduce 
the efficiency of these processes.15,16 The identi-
fication of mice with a loss-of-function mutation 
in the gene encoding GMAP-210 facilitates assess-
ment of the function of the Golgi structure in vivo. 
Although additional roles of GMAP-210 have been 
suggested,7,18-20 our in vivo data are most consis-
tent with its role in Golgi organization and pro-
tein processing.
Despite expression of GMAP-210 in many cell 
types, GMAP-210 deficiency altered Golgi archi-
tecture and caused swelling of the endoplasmic 
reticulum in a subgroup of tissues. Cells within the 
developing skeletal system — chondrocytes and 
osteoblasts — have very high rates of matrix se-
cretion21 and may be particularly susceptible to 
stress when Golgi processing is inefficient. Indeed, 
chondrocytes with mutant GMAP-210 showed 
clear evidence of stress in the endoplasmic reticu-
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Figure 5. Mutations in TRIP11 and Human Achondrogenesis Type 1A.
In Panel A, a radiograph of a 27-week-old human fetus with a diagnosis of 
achondrogenesis type 1A reveals a lack of mineralization in the skull and 
the vertebral column (arrows) and short limbs. The electron micrographs 
at the right show chondrocytes from two unrelated fetuses with achondro-
genesis type 1A, with swollen endoplasmic reticulum (arrows) and vesicu-
lar Golgi apparatus (arrowhead in upper image). In Panel B, the structure 
of the GMAP-210 protein is shown ith the r lative location and sizes of its 
21 coding exons indicated below. ALPS (amphipathic lipid sensor domain) 
and GRAB (GRIP-related Arf-binding domain) reportedly mediate interac-
tions between GMAP-210 and membranes in vitro. In the diagram below 
the protein, arrows point from the mutations that were identified in 10 un-
related patients with achondrogenesis type 1A to their approximate loca-
tions within the exons. Two mutations (c.202-2A→G and c.589-2A→G) af-
fect intronic splice-acceptor sites. Five mutations (p.R264X, p.R1028X, 
p.Q1160X, p.R1167X, and p.W1224X) are nonsense mutations. The remain-
ing mutations are frameshift mutations. Several patients, including those 
from consanguineous unions, were homozygous for mutations, whereas 
others were compound heterozygotes. Some mutations were found in 
more than one patient.
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lum, abnormal differentiation, and increased cell 
death. Impaired protein processing and swelling 
of the endoplasmic reticulum have been observed 
in other human skeletal dysplasias. Typically, these 
dysplasias have been caused by mutations in a se-
creted matrix protein that impair its folding and 
secretion. Examples include specific mutations 
of type I collagen in osteogenesis imperfecta,22 
type II collagen in spondyloepiphyseal dysplasia 
congenita,23 type X collagen in Schmid metaphy-
seal dysplasia,24 and cartilage oligomeric matrix 
protein in pseudoachondroplasia and multiple 
epiphyseal dysplasia.25 Investigators have identi-
fied mutations in patients with craniolenticular 
dysplasia that affect secretory mutant protein 23A 
(SEC23A), a protein involved in generating vesicles 
containing coat protein complex II that are used 
to move proteins from the endoplasmic reticu-
lum to the Golgi apparatus.26 The nonlethality of 
SEC23A deficiency may be explained by the co-
expression of its paralog, SEC23B, in most cell 
types.27,28 Mutations affecting trafficking protein 
particle complex 2 (TRAPPC2) and dymeclin, two 
other proteins thought to have roles in the trans-
port of proteins between the endoplasmic reticu-
lum and the Golgi apparatus, also cause nonlethal 
skeletal dysplasias — X-linked spondyloepiphyseal 
dysplasia tarda and the Dyggve–Melchior–Clausen 
syndrome, respectively.29-31 Therefore, it is reason-
able to postulate that the developing skeleton, be-
ing sensitive to defects in protein transport, will 
be affected by mutations in other components of 
the secretory pathways whose deficiency causes 
Golgi disorganization.
Important post-translational modifications, 
such as the synthesis of glycosaminoglycans, occur 
in the Golgi apparatus. Chondrocytes produce 
several highly modified proteoglycans, the most 
abundant of which is aggrecan, a very large pro-
teoglycan (measuring 500 nm and having a mass 
of 3 megadaltons) that contains hundreds of gly-
cosaminoglycan side chains.32 Immunofluores-
cence studies showed that aggrecan core protein 
was present in both wild-type and mutant car-
tilage, even though staining with Alcian blue, 
electron microscopy, and lectin staining suggest 
that this protein is improperly glycosylated in the 
mutant cartilage. In contrast, perlecan, a less 
abundant and smaller glycosaminoglycan contain-
ing proteoglycan, is abnormally retained within 
mutant chondrocytes and fibroblasts. These data 
suggest that GMAP-210 maintains the Golgi struc-
ture in chondrocytes, thereby facilitating complex 
glycosylation reactions while also participating in 
the transport of specific proteins. Indeed, RNAi 
knockdown of golgin-97 and golgin-245 has been 
shown to affect the secretion of E-cadherin and 
tumor necrosis factor α, respectively. However, 
depletion of these golgins did not affect the orga-
nization of the Golgi apparatus.33,34
Loss-of-function mutations in solute carrier 
family 26, member 2 (SLC26A2), which encodes a 
high-affinity sulfate transporter, cause achondro-
genesis type 1B, which is phenotypically similar to 
achondrogenesis type 1A.35 Impaired post-trans-
lational modification of proteoglycans in cartilage 
appears to be common to the two disorders.
Follit and colleagues described neonatal lethal-
ity in mice with a gene-trap insertion into Trip11.7 
Their studies focused on the role of GMAP-210 in 
the formation of the primary cilia and in intrafla-
gellar transport; they noted that cells from the 
mutant mice had shorter cilial than those from 
wild-type mice and that these cells failed to local-
ize intraflagellar transport protein 20 to the Golgi 
apparatus. Impaired cilial function has previously 
been shown to cause skeletal-patterning defects as 
well as skeletal dysplasia through disruption of 
hedgehog signaling.36,37 Our data suggest that 
neither impaired cilial function nor impaired 
hedgehog signaling is a primary contributor to the 
skeletal phenotype in mice lacking GMAP-210 
(Fig. 7 in the Supplementary Appendix). Decreased 
alveolar formation was observed in the lungs of 
gene-trap mutant mice,7 which we also observed 
in our mutant mice. We suggest that the lung 
phenotype is a consequence of the skeletal phe-
notype, since alveolar deficiency has been observed 
in other conditions characterized by insufficient 
thoracic volume.38
Although we found TRIP11 mutations in all 10 
patients with achondrogenesis type 1A that were 
tested, we cannot conclude that every case is at-
tributable to mutations in TRIP11. However, the 
identification of TRIP11 as the major disease-
causing gene makes it possible to conduct genetic 
testing in families with a history of achondrogen-
esis type 1A. It is notable that we did not observe 
missense mutations in patients with achondrogen-
esis type 1A, suggesting that milder mutations 
may result in a different clinical phenotype. For 
example, SNPs near TRIP11 have been associated 
with normal variation in human height.39,40
Forward genetic analysis has the potential to 
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provide insight into the molecular mechanisms 
of a biologic process that is novel and unexpected, 
since a phenotype-driven screen is not biased by 
preconceptions regarding gene function. In vitro 
knockdown of GMAP-210 had suggested that the 
absence of this protein would lead to Golgi frag-
mentation and dysfunction in all cells. Instead, 
a forward genetic screen in mutagenized mice 
indicated that the absence of GMAP-210 pre-
dominantly affects the development of the skel-
etal system. Our finding that patients with achon-
drogenesis type 1A, a phenotypically similar 
syndrome, also have mutations in TRIP11 that lead 
to GMAP-210 deficiency underscores the power 
and usefulness of this strategy of genetic inquiry.
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